Korean J Intern Med.
2007 Sep;22(3):178-185. 10.3904/kjim.2007.22.3.178.
Docetaxel Monotherapy as Second-Line Treatment for Pretreated Advanced Non-Small Cell Lung Cancer Patients
- Affiliations
-
- 1Lung Cancer Multidisciplinary Team of Kangnam St. Mary's Hospital, Division of Oncology, Department of Internal Medicine, The Catholic University of Korea, Seoul, Korea. jinkang@catholic.ac.kr
- 2Department of Radiology, The Catholic University of Korea, Seoul, Korea.
- 3Department of Nuclear Medicine, The Catholic University of Korea, Seoul, Korea.
- 4Department of Radiation Oncology, The Catholic University of Korea, Seoul, Korea.
- 5Division of Pulmonology, Department of Internal Medicine, The Catholic University of Korea, Seoul, Korea.
- 6Department of Chest Surgery, The Catholic University of Korea, Seoul, Korea.
- 7Department of Hospital Pathology, The Catholic University of Korea, Seoul, Korea.
- KMID: 1785624
- DOI: http://doi.org/10.3904/kjim.2007.22.3.178
Abstract
- BACKGROUND: Second-line chemotherapy offers advanced non-small cell lung cancer (NSCLC) patients a small, but significant increase in survival. Docetaxel is usually administered as a 3-week schedule, yet there is significant toxicity with this therapy. Therefore, a weekly schedule has been explored in several previous trials. In this retrospective study, we compared the efficacy and safety of a weekly schedule and a 3-week schedule of docetaxel monotherapy in a second-line setting. METHODS: Docetaxel was administered as 75 mg/m2 on day 1 every 3 weeks or as 37.5 mg/m2 on day 1 and 8 every 3 weeks until disease progression or severe toxicity developed. RESULTS: From October 2003 to March 2006, a total of 37 patients received docetaxel monotherapy and 36 patients could be evaluated. A total of 135 cycles were administered and then evaluated. The median overall survival was 13.3 months (95% confidence interval: 6.3~20.3) for the weekly schedule and 10.7 months (95% confidence interval: 8.3~13.0) for the 3-week schedule (p=0.41). The median time to progression was 3.0 months (95% confidence interval: 1.9~4.0) and 2.8 months (95% confidence interval: 1.0~4.6), respectively (p=0.41). The response rate was 16.7% for the weekly schedule and 21.1% for the 3-week schedule. The major form of hematologic toxicity was grade 3-4 neutropenia (3-week: 38.9%, weekly: 9.5%). The non-hematologic toxicities were similar between the two schedules. There were no treatment-related deaths. CONCLUSIONS: A docetaxel weekly schedule was very tolerable and it had comparable activity to that of the 3-week docetaxel schedule. Considering the efficacy and tolerability, a docetaxel weekly schedule can be an alternative schedule for the standard treatment of NSCLC in a second-line setting.
Keyword
MeSH Terms
-
Adult
Aged
Antineoplastic Agents/*administration & dosage/adverse effects
Carcinoma, Non-Small-Cell Lung/*drug therapy/pathology
Drug Administration Schedule
Female
Humans
Lung Neoplasms/*drug therapy/pathology
Male
Middle Aged
Neoplasm Staging
Retrospective Studies
Taxoids/*administration & dosage/adverse effects
Treatment Outcome
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Docetaxel as Second-line Monotherapy for Advanced Non-small Cell Lung Cancer
- Cell Death Induction Mechanism of Non-small Cell Lung Cancer Cell Line, NCI-H1703 by Docetaxel
- Weekly Low-Dose Docetaxel for Salvage Chemotherapy in Pretreated Elderly or Poor Performance Status Patients with Non-small Cell Lung Cancer
- Comparison of Gefitinib versus Docetaxel in Patients with Pre-Treated Non-Small Cell Lung Cancer (NSCLC)
- Treatment of Advanced and Metastatic Squamous Non-small Cell Lung Cancer
